Cite
MLA Citation
Saad Z Usmani et al.. “Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.” Lancet oncology, vol. 23, no. 1, 2022, pp. 65–76. http://access.bl.uk/ark:/81055/vdc_100148167817.0x00000f